Idorsia’s Tryvio Receives the US FDA’s Approval for the Treatment of Hypertension
Shots:
- The US FDA has approved Tryvio (12.5mg, oral, QD, with/without food) in addition with antihypertensive drugs to treat hypertensive adults not controlled on other drugs
- The P-III (PRECISION) trial assessed the efficacy of Tryvio for hypertensive adults with SBP ≥140 mmHg receiving at least 3 antihypertensive therapies with the 1EP as change in SiSBP at wk.4 & 2EP as change in SiSBP from wk.36 to wk.40
- In the study post 4wks. PBO run-in duration, patients (n=730) in part 1 were administered Tryvio (12.5mg, 25mg, or PBO, QD) for 4wks., all patients were then administered Tryvio (25mg, QD) for 32wks. in part 2 & post 32wks. patients were re-randomized to receive Tryvio (25mg) or PBO for a 12wk. withdrawal period in part 3
Ref: Idorsia | Image: Idorsia
Related News:- Viatris Collaborates with Idorsia to Develop and Commercialize Selatogrel and Cenerimod
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
